AMRX Stock Overview
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amneal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.41 |
| 52 Week High | US$9.48 |
| 52 Week Low | US$4.16 |
| Beta | 1.17 |
| 11 Month Change | -0.71% |
| 3 Month Change | 4.47% |
| 1 Year Change | 88.99% |
| 33 Year Change | 82.03% |
| 5 Year Change | 156.40% |
| Change since IPO | -43.97% |
Recent News & Updates
Recent updates
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Amneal Pharmaceuticals: A Small 'Thumbs Up'
Oct 28Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet
Sep 01Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Aug 31Amneal Pharmaceuticals Q2 2022 Earnings Preview
Aug 04Shareholder Returns
| AMRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.9% | -3.8% | -1.0% |
| 1Y | 89.0% | 9.8% | 30.3% |
Return vs Industry: AMRX exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: AMRX exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| AMRX volatility | |
|---|---|
| AMRX Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMRX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,850 | Chirag Patel | amneal.com |
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Amneal Pharmaceuticals, Inc. Fundamentals Summary
| AMRX fundamental statistics | |
|---|---|
| Market cap | US$2.62b |
| Earnings (TTM) | -US$184.45m |
| Revenue (TTM) | US$2.68b |
1.0x
P/S Ratio-14.1x
P/E RatioIs AMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRX income statement (TTM) | |
|---|---|
| Revenue | US$2.68b |
| Cost of Revenue | US$1.70b |
| Gross Profit | US$979.05m |
| Other Expenses | US$1.16b |
| Earnings | -US$184.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 36.53% |
| Net Profit Margin | -6.88% |
| Debt/Equity Ratio | -7,524.6% |
How did AMRX perform over the long term?
See historical performance and comparison